A phase ii trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest oncology group study 8904

Keyphrases

• Phase II Trial 100%
• Platinum-based 100%
• Group Studies 100%
• Platinum-based Chemotherapy 100%
• No Response 100%
• Southwest Oncology Group 100%
• Advanced Ovarian Carcinoma 100%
• Disease Persistence 100%
• Doxorubicin 50%
• Accruals 50%
• Response Rate 50%
• Statistical Design 50%
• Dose Escalation 50%
• Myelosuppression 50%
• Adverse Cardiac Events 50%
• Neutropenia 50%
• Initial Treatment 50%
• Starting Dose 50%
• Recurrent Ovarian Cancer 50%
• 5-cycle 50%
• Anthrapyrazoles 50%

Medicine and Dentistry

• Chemotherapy 100%
• Krukenberg Tumor 100%
• Oncology 100%
• Oxanthrazole 100%
• Diseases 40%
• Recurrent Disease 40%
• Neutropenia 20%
• Phase II Trials 20%
• Bone Marrow Suppression 20%
• Recurrent Ovarian Cancer 20%
• Doxorubicin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Ovary Carcinoma 100%
• Oxanthrazole 100%
• Recurrent Disease 40%
• Disease 40%
• Doxorubicin 20%
• Phase II Trials 20%
• Ovary Cancer 20%
• Bone Marrow Suppression 20%
• Neutropenia 20%